Ellsworth Advisors LLC Sells 218 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

Ellsworth Advisors LLC decreased its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 1.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 20,570 shares of the medical research company’s stock after selling 218 shares during the quarter. Ellsworth Advisors LLC’s holdings in Charles River Laboratories International were worth $3,797,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently modified their holdings of the business. Versant Capital Management Inc lifted its position in Charles River Laboratories International by 1,071.4% during the fourth quarter. Versant Capital Management Inc now owns 164 shares of the medical research company’s stock valued at $30,000 after purchasing an additional 150 shares during the last quarter. Wolff Wiese Magana LLC purchased a new stake in shares of Charles River Laboratories International during the 3rd quarter valued at $32,000. Pinnacle Bancorp Inc. lifted its holdings in shares of Charles River Laboratories International by 52.0% during the 4th quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company’s stock worth $35,000 after acquiring an additional 65 shares during the last quarter. Assetmark Inc. grew its position in Charles River Laboratories International by 1,153.3% in the third quarter. Assetmark Inc. now owns 188 shares of the medical research company’s stock worth $37,000 after acquiring an additional 173 shares in the last quarter. Finally, ORG Wealth Partners LLC bought a new position in Charles River Laboratories International in the fourth quarter valued at $56,000. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Charles River Laboratories International Price Performance

CRL opened at $163.77 on Monday. The stock’s 50 day moving average price is $190.64 and its 200-day moving average price is $198.40. Charles River Laboratories International, Inc. has a 52-week low of $160.85 and a 52-week high of $275.00. The stock has a market capitalization of $8.37 billion, a PE ratio of 20.50, a price-to-earnings-growth ratio of 6.62 and a beta of 1.38. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.14 and a current ratio of 1.48.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings data on Wednesday, November 6th. The medical research company reported $2.59 EPS for the quarter, topping the consensus estimate of $2.43 by $0.16. Charles River Laboratories International had a net margin of 10.44% and a return on equity of 14.29%. The business had revenue of $1.01 billion during the quarter, compared to analyst estimates of $975.99 million. During the same period in the prior year, the business earned $2.72 EPS. The company’s revenue for the quarter was down 1.6% on a year-over-year basis. On average, equities research analysts predict that Charles River Laboratories International, Inc. will post 10.18 EPS for the current year.

Analyst Ratings Changes

A number of brokerages recently weighed in on CRL. Redburn Atlantic assumed coverage on Charles River Laboratories International in a report on Monday, October 14th. They set a “sell” rating and a $151.00 price objective on the stock. TD Cowen lifted their price target on shares of Charles River Laboratories International from $203.00 to $227.00 and gave the stock a “hold” rating in a research note on Monday, November 11th. Citigroup cut shares of Charles River Laboratories International from a “neutral” rating to a “sell” rating and cut their price objective for the company from $215.00 to $175.00 in a research note on Tuesday, October 1st. CLSA cut shares of Charles River Laboratories International from a “hold” rating to an “underperform” rating and set a $164.00 target price on the stock. in a research report on Monday, November 18th. Finally, Bank of America cut their price target on shares of Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating for the company in a research report on Friday, December 13th. Three equities research analysts have rated the stock with a sell rating, twelve have assigned a hold rating and two have given a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $209.00.

Insider Buying and Selling at Charles River Laboratories International

In other Charles River Laboratories International news, Director Richard F. Wallman sold 6,621 shares of the firm’s stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $216.12, for a total transaction of $1,430,930.52. Following the completion of the transaction, the director now owns 12,386 shares of the company’s stock, valued at approximately $2,676,862.32. This trade represents a 34.83 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 1.30% of the company’s stock.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).